Cell Signaling Technology

Product Pathways - Motif Antibodies

Acetylated-Lysine Mouse mAb (Ac-K-103) #9681

Applications Reactivity Source Isotype
W E-P All Mouse IgG2a

Applications Key:  W=Western Blotting  E-P=ELISA (Peptide)
Reactivity Key: All=All species expected

Specificity / Sensitivity

Acetylated-Lysine Mouse mAb (Ac-K-103) detects proteins only when posttranslationally modified by acetylation on the epsilon-amine groups of lysine residues. Detection of acetylated lysine by this antibody is largely independent of surrounding amino acid sequence. The antibody has been shown to recognize acetylated proteins including histones, p53, CBP, PCAF and chemically acetylated BSA. (U.S. Patent No's.: 6,441,140; 6,982,318; 7,259,022; 7,344,714; U.S.S.N. 11,484,485; and all foreign equivalents.)

Source / Purification

Monoclonal antibodies are produced by immunizing mice with a synthetic acetylated lysine-containing peptide (KLH-coupled).

Western Blotting

Western Blotting

Western blot analysis of extracts from COS cells, untreated or TSA-treated (0.4 µM for 18 hours), using Acetylated-Lysine Mouse mAb (Ac-K-103).

Western Blotting

Western Blotting

Western blot analysis of extracts from NIH/3T3 cells, untreated (lane 2) or treated in vitro with CPB (lane 3) or PCAF (lane 4), using Acetylated-Lysine Mouse mAb (Ac-K-103). (Lanes 1 and 5: PCAF and CBP, respectively, showing auto acetylation.

Background

Acetylation of lysine, like phosphorylation of serine, threonine or tyrosine, is an important reversible modification controlling protein activity. The conserved amino-terminal domains of the four core histones (H2A, H2B, H3 and H4) contain lysines that are acetylated by histone acetyltransferases (HATs) and deacetylated by histone deacetylases (HDACs) (1). Signaling resulting in acetylation/deacetylation of histones, transcription factors and other proteins affects a diverse array of cellular processes including chromatin structure and gene activity, cell growth, differentiation and apoptosis (2-6). The regulation of protein acetylation status is impaired in the pathologies of cancer and polyglutamine diseases (7), and HDACs have become promising targets for anti-cancer drugs currently in development (8).

  1. Hassig, C.A. and Schreiber, S.L. (1997) Curr Opin Chem Biol 1, 300-8.
  2. Allfrey, V. G. et al. (1964) Proc. Natl. Acad. Sci. USA 51, 786-794.
  3. Liu, L. et al. (1999) Mol. Cell. Biol. 19(2), 1202-1209.
  4. Boyes, J. et al. (1998) Nature 396, 594-8.
  5. Polevoda, B. and Sherman, F. (2002) Genome Biol. 3, Reviews0006.
  6. Yoshida, M. et al. (2003) Prog. Cell Cycle Res. 5, 269-278.
  7. Hughes, R.E. (2002) Curr. Biol. 12, R141-R143.
  8. Vigushin, D.M. and Coombes, R.C. (2004) Curr. Cancer Drug Targets 4, 205-218.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

License/Use Restrictions: Use of CST Motif Antibodies within certain methods (e.g., U.S. Patent No.'s 7,198,896 & 7,300,753) may require a license from CST. For information regarding academic licensing terms please have your technology transfer office contact CST Legal Department at CST_ip@cellsignal.com. For information regarding commerical licensing terms please contact CST Business Development at cbunker@cellsignal.com.

Product Pathways

Drug Discovery Tools

Featured Technologies

Protein Classes